Moleculin Biotech, Inc.

Contributing Author

Recent Articles by Moleculin Biotech, Inc.

1 hour	Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill MBRX GlobeNewswire
Oct-30	Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia "MIRACLE" Clinical Trial at the 14th Annual Acute Leukemia Meeting MBRX GlobeNewswire
Oct-29	Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin MBRX GlobeNewswire
Oct-23	Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer MBRX GlobeNewswire
Sep-25	Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin MBRX GlobeNewswire
Sep-09	Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia "MIRACLE" Clinical Trial MBRX GlobeNewswire
Sep-08	Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia MBRX GlobeNewswire
Aug-28	Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds MBRX GlobeNewswire
Aug-27	Moleculin Issues New Positive AML Overall Survival Data: MBRX GlobeNewswire
Aug-14	Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech MBRX GlobeNewswire
Aug-13	Moleculin Reports Second Quarter 2025 Financial Results and Highlights MBRX GlobeNewswire
Aug-06	Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment MBRX GlobeNewswire
Jul-30	Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin MBRX GlobeNewswire
Jul-22	Moleculin Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference MBRX GlobeNewswire
Jul-17	Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships MBRX GlobeNewswire
Jul-09	Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans MBRX GlobeNewswire
Jun-20	Moleculin Announces $5.9 Million Public Offering MBRX GlobeNewswire
Jun-18	Moleculin Participates in Virtual Investor "What This Means" Segment MBRX GlobeNewswire
Jun-18	Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML MBRX GlobeNewswire
Jun-11	Moleculin Participates in Virtual Investor "What This Means" Segment MBRX GlobeNewswire
Jun-05	Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107) MBRX GlobeNewswire
Jun-04	Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) MBRX GlobeNewswire
May-14	Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update MBRX GlobeNewswire
May-12	Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial MBRX GlobeNewswire
May-07	Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast MBRX GlobeNewswire
May-06	Moleculin Announces World Health Organization Approval of "naxtarubicin" as International Non-Proprietary Name for Annamycin MBRX GlobeNewswire
May-05	Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents MBRX GlobeNewswire

Moleculin Biotech, Inc.

Recent Articles by Moleculin Biotech, Inc.

Upgrade your FINVIZ experience